3i Investments plc

TORONTO, April 29 /CNW/ - 3i Investments plc of London, England announces
that 3i Group plc (hereinafter referred to as "3i") and 3i Bioscience
Investment Trust plc ("3i Bioscience") have purchased 6,772,469 common shares
of Inflazyme Pharmaceuticals Ltd. As a result of the purchase, 3i holds
5,079,315 common shares (or 5.431%) of Inflazyme's common stock and 3i
Bioscience holds 4,683,154 common shares (or 5.007%) of Inflazyme's common
stock. 3i and 3i Bioscience received the shares of Inflazyme as consideration
for the sale of shares in Adprotech Ltd. 
The purchases have been made for investment purposes only, and not with
the purpose of influencing the control or direction of Inflazyme. 3i and 3i
Bioscience may, subject to market conditions, make additional investments in
or dispositions of securities of Inflazyme, including additional purchases or
sales of shares of common stock. 3i and 3i Bioscience do not, however, intend
to acquire 20% of any class of the outstanding voting or equity securities of
Inflazyme. 
-0-                           04/29/2004 
/For further information: please contact Andy Smith, 3i Investments plc, 
91 Waterloo Road, London, SE1 8XP, England, Tel: +44 (0) 20 7975 3144, 
Fax: +44 (0) 20 7975 3014/ 
CO:  3i Investments plc
ST:  Ontario
IN:  
SU:  TNM  
-30- 
-0- Apr/29/2004 20:14 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.